Comparing a new drug to standard chemo for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called datopotamab deruxtecan against a standard chemotherapy (docetaxel) for people with a certain type of advanced lung cancer (non-squamous non-small cell lung cancer) that has already been treated. The new drug targets a protein called TROP2 found on cancer cells, which may help slow or stop the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-squamous non-small cell lung cancer that has spread (stage IIIB, IIIC, or IV).
- Your cancer has gotten worse after receiving platinum-based chemotherapy and an immunotherapy drug (like pembrolizumab or nivolumab).
- You have not had certain genetic changes (like EGFR, ALK, ROS1) that have approved targeted treatments.
- Your tumor must have a protein called TROP2, which will be checked by a special test.
- You are well enough to carry out daily activities (ECOG performance status 0 or 1).
- You have at least one tumor that can be measured and has not been previously treated with radiation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (setidegrasib) against a standard chemo drug (docetaxel) for people with a specific type of advanced lung cancer that has a KRAS G12D mutation. The goal is to see which treatment works better.
This trial tests a new two-drug combination (Dato-DXd and an immunotherapy called rilvegostomig) as the first treatment for people with advanced non-squamous lung cancer who have high PD-L1 levels. The goal is to see if this combination works better than current standard options.
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
This trial tests new treatments for people with stage IV nonsquamous non-small cell lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It aims to find better options for those whose cancer has specific genetic features.
This study tests a new drug (7MW3711) against a standard chemotherapy (docetaxel) for people with advanced squamous non-small cell lung cancer that has progressed after prior chemo-immunotherapy. The goal is to see if the new drug is more effective or has fewer side effects.
This trial tests whether two different PET scans can help doctors see how well a new type of targeted therapy (called a TROP2 ADC) is working in people with a specific kind of advanced lung cancer that has stopped responding to standard pills. The goal is to find the best way to monitor treatment and potentially improve outcomes.
Hear when a new Non-small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.